SIMO vs PHIO

Silicon Motion Technology Corporation (SIMO) offers the better valuation at 16.

6x trailing P/E (29. 9x forward), making it the more compelling value choice. Analysts rate Silicon Motion Technology Corporation (SIMO) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Silicon Motion Technology Corporation (SIMO) delivered a total return of +267.

4%, compared to -99. 6% for Phio Pharmaceuticals Corp. (PHIO). Over 10 years, the gap is even starker: SIMO returned +533. 8% versus PHIO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Phio Pharmaceuticals Corp.

(PHIO) is the lower-risk stock at 1. 59β versus Silicon Motion Technology Corporation's 1. 90β — meaning SIMO is approximately 19% more volatile than PHIO relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Silicon Motion Technology Corporation grew EPS 38.

3% year-over-year, compared to -59. 3% for Phio Pharmaceuticals Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Silicon Motion Technology Corporation (SIMO) is the more profitable company, earning 13.

9% net margin versus 0. 0% for Phio Pharmaceuticals Corp. — meaning it keeps 13. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SIMO leads at 10. 5% versus 0. 0% for PHIO. At the gross margin level — before operating expenses — SIMO leads at 48. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, SIMO (3.

3% yield) pays a dividend. PHIO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Silicon Motion Technology Corporation (SIMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (3.

3% yield, +533. 8% 10Y return). Phio Pharmaceuticals Corp. (PHIO) carries a higher beta of 1. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIMO: +533. 8%, PHIO: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SIMO (Technology) and PHIO (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SIMO is a small-cap deep-value stock; PHIO is a small-cap quality compounder stock. SIMO pays a dividend while PHIO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.